Hepatitis/MASH

Novel drug RG-101 could shorten the treatment time for hepatitis C virus (HCV) infection to 4 weeks.

Zepatier achieves sustained virologic response rate of 99.2% during a 12 to 16 week treatment course in patients with HCV.

Top news of the day from across the health care landscape.

HCV testing rises in substance use disorder treatment programs.

Zepatier boasts sustained virologic response rates of 99% in hepatitis C genotypes 1 and 4.

Zepatier boasts sustained virologic response rates of 99% in hepatitis C genotypes 1 and 4.

Researchers consider whether eradicating HCV and HBV is an obtainable goal given the high cost of antiviral drugs.

Avella Specialty Pharmacy has launched two innovative apps to help providers select the most appropriate specialty drug options for hepatitis C and oncology patients.

Descovy is not a complete regimen and must be used in combination with other antiretroviral agents for the treatment of HIV.

California man with osteogenesis imperfecta beats HCV after treatment with Harvoni.

HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.

One clinic found little value in the early testing of infants born to HCV-infected mothers.

Is sofosbuvir plus ribavirin a viable option for hepatitis C virus therapy after liver transplant?

Study finds a common assortment of reasons for non-initiation of hepatitis C therapy, regardless of patient race or ethnicity.

Aberrant protein mutation associated with the black plague may lead to treatments for HIV and hepatitis C.

The high cost of HCV treatment remains a hurdle for patients, payers, and providers.

Possible side effects for multiple sclerosis medications can range from mild to life-threatening.

Deaths related to liver cancer from hepatitis C virus increase during a time when overall cancer deaths continue to decline.

Expanded federal funding allows Department of Veterans Affairs to fund care for all veterans with hepatitis C.

Special considerations must be made when treating patients infected with both HIV and hepatitis C virus.

Approximately 2.3 million people worldwide are infected with both HIV and hepatitis C virus.

Merck has applauded the US Department of Veterans Affairs for broadening access to treatment for Veterans with chronic hepatitis C virus infection.

Major breakthroughs in hepatitis C virus research hold promise for patient care and control of viral global health crises.

Zepatier can be used with or without ribavirin and does not require interferon.

Research addresses whether the prior authorization process creates a barrier to timely and effective care for hepatitis C.